<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Int J Endocrinol Metab</journal-id><journal-id journal-id-type="doi">10.5812/ijem</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>International Journal of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1726-913X</issn><issn pub-type="epub">1726-9148</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25745491</article-id><article-id pub-id-type="pmc">4338654</article-id><article-id pub-id-type="doi">10.5812/ijem.17988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Ghrelin and Estradiol on Mean Concentration of Thyroid Hormones</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kordi</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="aff48803">1</xref></contrib><contrib contrib-type="author"><name><surname>Khazali</surname><given-names>Homayoun</given-names></name><xref ref-type="aff" rid="aff48803">1</xref><xref ref-type="corresp" rid="cor48804">*</xref></contrib></contrib-group><aff id="aff48803"><label>1</label>Department of Physiology, Shahid Beheshti University, Tehran, IR Iran</aff><author-notes><corresp id="cor48804"><label>*</label>Corresponding author: Homayoun Khazali, Department of Physiology, Shahid Beheshti University, Tehran, IR Iran. Tel: +98-9121254041, E-mail: <email>hkhazali@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2015</year></pub-date><volume>13</volume><issue>1</issue><elocation-id>e17988</elocation-id><history><date date-type="received"><day>02</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>04</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Research Institute For Endocrine Sciences and Iran Endocrine Society.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Ghrelin is a novel peptide hormone that has GH releasing activity and also other endocrine and metabolic functions. It can also increase food intake and decrease T3 and T4 concentrations. Several parameters of hypothalamic-pituitary-thyroid (HPT) axis function are modulated by 17&#x003b2;-estradiol (E2).</p></sec><sec><title>Objectives:</title><p>The purpose of this study was to investigate the effect of interactions between ghrelin and estradiol (injected via ICV route) on plasma T3 and T4 concentrations in female rats.</p></sec><sec><title>Materials and Methods:</title><p>Eighteen Wistar female rats (bodyweight, 200-250 g) were randomly divided into three groups. Group 1 received estradiol, Group 2 received ghrelin and Group 3 received ghrelin and estradiol. Plasma samples were used to assess T3 and T4 concentration by RIA.</p></sec><sec><title>Results:</title><p>The results indicated that ghrelin significantly decreased thyroid hormone concentrations, whereas estradiol increased these concentrations. The simultaneous injection of ghrelin and estradiol significantly decreased the inhibitory effect of ghrelin on thyroid hormone concentrations (P &#x0003c; 0.05).</p></sec><sec><title>Conclusions:</title><p>According to the results of this study, both ghrelin and estradiol affect the concentration of thyroid hormone but in opposite directions. This difference might be due to different underlying hormonal mechanisms such as HPA and/or HPT axis melanocyte stimulating hormone (MSH) systems could be suggested.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Ghrelin</kwd><kwd>Estradiol</kwd><kwd>Injection</kwd></kwd-group></article-meta></front><body><sec id="sec79146"><title>1. Background</title><p>Ghrelin, as a novel peptide hormone, has the growth-hormone-releasing activity and also other endocrine and metabolic functions (<xref rid="A17988R1" ref-type="bibr">1</xref>). Ghrelin is a multifunctional hormone secreted primarily from the stomach (<xref rid="A17988R2" ref-type="bibr">2</xref>). It is primarily found as an endogenous ligand for the growth-hormone secretagogue receptor; it is also an appetite stimulating hormone in the regulation of energy homeostasis (<xref rid="A17988R3" ref-type="bibr">3</xref>). It consists of 28 amino acids and the n-octanoylation of serine-3 position in the molecule is necessary for its bioactivity (<xref rid="A17988R4" ref-type="bibr">4</xref>). During fasting, ghrelin is secreted by X/A-like cells of stomach, neurons of hypothalamus and other tissues (<xref rid="A17988R2" ref-type="bibr">2</xref>, <xref rid="A17988R4" ref-type="bibr">4</xref>). Ghrelin can increase the growth-hormone secretions and food intake (<xref rid="A17988R5" ref-type="bibr">5</xref>, <xref rid="A17988R6" ref-type="bibr">6</xref>). The full-length preproghrelin is homologous to the promotilin protein classified in the motilin family, and is cleaved into the following two chains: 1) ghrelin and 2) obestatin (<xref rid="A17988R7" ref-type="bibr">7</xref>). Ghrelin receptors are expressed in a wide variety of tissues, including the pituitary, stomach, intestine, pancreas, thymus, gonads, thyroid, and heart. The diversity of ghrelin receptor locations suggests ghrelin has the diverse biological functions (<xref rid="A17988R8" ref-type="bibr">8</xref>). It decreases energy expenditure and suppresses TSH secretion. Previous studies have shown that ghrelin decreases the activity of hypothalamus-pituitary-thyroid axis (<xref rid="A17988R6" ref-type="bibr">6</xref>, <xref rid="A17988R9" ref-type="bibr">9</xref>-<xref rid="A17988R13" ref-type="bibr">13</xref>). It is also proved that ghrelin can increase the appetite via agouti-related protein and neuropeptide Y (NPY) pathway and can also decrease the T3 and T4 secretion (<xref rid="A17988R6" ref-type="bibr">6</xref>, <xref rid="A17988R13" ref-type="bibr">13</xref>). In addition, studies have shown that ghrelin can increase the growth-hormone release (<xref rid="A17988R14" ref-type="bibr">14</xref>), gastric-emptying rate, appetite and body weight (<xref rid="A17988R4" ref-type="bibr">4</xref>, <xref rid="A17988R15" ref-type="bibr">15</xref>) and also stimulate the secretion of adrenocorticotropic hormone and inhibition of thyroid hormone concentrations. The hypothalamus-pituitary-thyroid axis plays an important role in the regulation of metabolism and energy homeostasis through thyroid hormones. It has been shown that different neural, hormonal and environmental factors interact to modulate thyroid hormones secretions. Estradiol (E2 or 17&#x003b2;-estradiol, also oestradiol) is a sex hormone. Estradiol is abbreviated E2 as it has two hydroxyl groups in its molecular structure (<xref rid="A17988R16" ref-type="bibr">16</xref>). In the female, estradiol acts as a growth hormone for tissue of the reproductive organs, supporting the lining of the vagina, the cervical glands, the endometrium, and the lining of the fallopian tubes. It enhances growth of the myometrium. Estradiol appears necessary to maintain oocytes in the ovary. The central event in female reproduction is the surge release of luteinizing hormone from anterior pituitary gonadotroph (<xref rid="A17988R17" ref-type="bibr">17</xref>). These cells are controlled by a network of gonadotroping hormone neurons that project to the median eminence where they make a neurohemal contact with portal capillaries serving the anterior pituitary (<xref rid="A17988R18" ref-type="bibr">18</xref>-<xref rid="A17988R20" ref-type="bibr">20</xref>) The highest level of the receptors was found in the periventricular nucleus of the preoptic area, while low but detectable levels of the receptors were found in such limbic regions as the nucleus of the diagonal band, the olfactory tubercle and the cingulate cortex (<xref rid="A17988R18" ref-type="bibr">18</xref>). Regions that were devoid of detectable receptor included the medial septum, the parietal cortex, and the ventral thalamus. Menopause marks the end of the reproductive life span of women and is characterized by a dramatic drop of circulating estrogen hormone replacement therapy has been successfully used to treat the symptoms of menopause because estrogen has a strong suppressive effect on rat (<xref rid="A17988R19" ref-type="bibr">19</xref>). Estrogen and androgen administration modulate the pituitary-thyroid axis through alterations in thyroid hormone-binding globulin metabolism, but the effect of sex steroids on extrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion in rats are unknown. It has been suggested that the female rat steroids stimulate thyroid growth (<xref rid="A17988R20" ref-type="bibr">20</xref>). Seventeen beta-estradiol, the major estrogen in the body, acts via estrogen receptors present in the nucleus of the cell (<xref rid="A17988R21" ref-type="bibr">21</xref>, <xref rid="A17988R22" ref-type="bibr">22</xref>). Hypothalamus-pituitary-thyroid axis plays an important role in the regulation of metabolism and energy homeostasis through thyroid hormones (<xref rid="A17988R22" ref-type="bibr">22</xref>, <xref rid="A17988R23" ref-type="bibr">23</xref>). There is no evidence to support the effect of estradiol on the thyroid axis. This study was designed to examine the effect of ghrelin and estradiol on mean plasma T3 and T4 concentrations. In the present study, the effect of an interaction between ghrelin and estradiol on thyroid axis activity was investigated for the first time.</p></sec><sec id="sec79147"><title>2. Objectives</title><p>The purpose of this study was to examine the effect of the interaction between ghrelin and estradiol (injected via ICV route) on mean plasma T3 and T4 concentrations in female rats.</p></sec><sec id="sec79154"><title>3. Materials and Methods</title><sec id="sec79148"><title>3.1. Experimental Design</title><p>Eighteen adult female wistar rats weighing 200-250 g were randomly divided into three groups (provided by the center of neuroscience research of Shahid Beheshti University) were housed individually in cages under the controlled temperature (22 &#x000b1; 2) and light (12 h light/dark cycle). They had free access to food and water all the time. Eighteen wistar female rats (200-250 g/BW) were randomly divided into three groups. Groups 1 received ghrelin, group 2 received estradiol and group 3 received ghrelin and estradiol (via third ventricle). Animal surgery procedures and handling were carried out as previously described. Animals were anesthetized by IP injection of a mixture of ketamine and xylazine (100 mg/kg BW ketamine + 15 mg/kg BW xylazine; Alfasan Co., Holland).</p></sec><sec id="sec79149"><title>3.2. Third Ventricle Cannulation</title><p>For ICV injections, animals were placed into a stereotaxic frame and a 22-gauge stainless steel cannula was implanted into the third ventricle. The cannula was secured to the skull with three stainless steel screws and dental cement. The animals were kept in the individual cages and habituated by handling every day to minimize the stress of surgery. After a one-week recovery period, in the previous paper, the effective dose of ghrelin administered IV was 5 nmol (<xref rid="A17988R24" ref-type="bibr">24</xref>) and the effective dose of estradiol was 50 &#x000b5;g /mL (<xref rid="A17988R18" ref-type="bibr">18</xref>) (Ghrelin and estradiol provided by Ana Spec Co, USA). Ghrelin was dissolved in 100 &#x000b5;L of 0.9% saline and estradiol dissolved in olive oil. Ghrelin and estradiol were injected by a 27-gauge stainless steel injector, which connected to 10 &#x000b5;L Hamilton micro syringe (model 9435, Australia) by PE-20 tubing.</p></sec><sec id="sec79150"><title>3.3. Blood Collection</title><p>Blood samples were collected from tail vein and immediately centrifuged at 3500 rpm and the plasma samples were stored at -20 &#x000b0;C until the T3 and T4 concentrations were assayed. At the end of the experimentation, the blood samples were collected daily starting from one day before the injection until 30, 360,720, 1440 minutes and 4 days after the injection. Heparin was used in samples to prevent clotting.</p></sec><sec id="sec79151"><title>3.4. Brain Removal</title><p>The animal brains were removed and kept in formalin (10%) for two weeks. The correct ICV cannulae placement was confirmed histologically. Only those animals with properly positioned cannulae were included in the data analysis.</p></sec><sec id="sec79152"><title>3.5. Hormone Assay</title><p>The mean plasma T3 and T4 concentrations were measured. Plasma T3 and T4 concentrations were measured by T3 and T4 Kits and the method of a homologus double-antibody radioimmunoassay. Sensitivities of the T3 and T4 assays were 0.0046 and 0.54 mg/dL, respectively. </p></sec><sec id="sec79153"><title>3.6. Statistical Analysis</title><p>SPSS version19 (IBM, USA, 2010) was used for statistical analysis. The one-sample Shapiro-Wilk test was performed to determine normal distribution of the data. Results were expressed as mean &#x000b1; SD. Data were analyzed using repeated-measures ANOVA. P&#x0003c; 0.05 was considered significant statistically. </p></sec></sec><sec id="sec79158"><title>4. Results</title><sec id="sec79155"><title>4.1. Effects of Ghrelin Injection </title><p>Intraventricular injection of 5 nmol ghrelin significantly decreased plasma levels of T3 and T4 at 30 minutes after injection (P &#x0003c; 0. 05), but it has not been significant in the other steps of blood collection.</p></sec><sec id="sec79156"><title>4.2. Effects of Estradiol Injection </title><p>Intraventricular injection of 50 &#x003bc;g/kg E2 significantly increased plasma concentration of T3 and T4 at 30, 360, and 720 minutes after the injection (P &#x0003c; 0. 05) and in these steps we have had a minor increase but it has been significant in the other steps of blood collection.</p></sec><sec id="sec79157"><title>4.3. Effects of Estradiol and Ghrelin </title><p>Intraventricular injection of 5 nmol ghrelin and 50 &#x003bc;g/kg E2 increased plasma concentrations of T3 and T4 at 30, 360 and 720 minutes after the injection (P &#x0003c; 0.05) and in these steps we have had a minor increase but it has been significant in the other steps of blood collection.</p><table-wrap id="tbl20053" orientation="portrait" position="float"><label>Table 1.</label><caption><title> The effect of Ghrelin and Estradiol on Plasma Concentration of Thyroid Hormones <sup><xref ref-type="table-fn" rid="fn17480">a</xref>,<xref ref-type="table-fn" rid="fn17481">b</xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th style="border-bottom:solid thin;" colspan="2" rowspan="1">Ghrelin</th><th style="border-bottom:solid thin;" colspan="2" rowspan="1">Estradiol</th><th style="border-bottom:solid thin;" colspan="2" rowspan="1">Ghrelin and Estradiol</th></tr><tr><th style="vertical-align: middle;" rowspan="1" colspan="1">T3</th><th style="vertical-align: middle;" rowspan="1" colspan="1">T4</th><th style="vertical-align: middle;" rowspan="1" colspan="1">T3</th><th style="vertical-align: middle;" rowspan="1" colspan="1">T4</th><th style="vertical-align: middle;" rowspan="1" colspan="1">T3</th><th style="vertical-align: middle;" rowspan="1" colspan="1">T4</th></tr></thead><tbody><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>One day before injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">0.46 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">14.14 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">0.47 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">14.2 &#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.45 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">13.85 &#x000b1; 0.005</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>At 30 minutes after injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">0.21 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">7.5 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">0.71 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">21.7&#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.59 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">18.5 &#x000b1; 0.005</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>At 360 minutes after injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">0.42 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">13.5 &#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.68 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">19.6 &#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.55 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">17.5&#x000b1; 0.051</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>At 720 minutes after injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">0.43 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">13.6 &#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.66 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">17.8 &#x000b1; 0.051</td><td style="text-align: center;" rowspan="1" colspan="1">0.53 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">17 &#x000b1; 0.051</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>At 1440 minutes after injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">0.44 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">14 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">0.47 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">14.5 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">0.47 &#x000b1; 0.005</td><td style="text-align: center;" rowspan="1" colspan="1">14.3 &#x000b1; 0.051</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Four days after injection </bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.44 &#x000b1; 0.005</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">14 &#x000b1; 0.051</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.48 &#x000b1; 0.005</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">14.57 &#x000b1; 0.005</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">0.49 &#x000b1; 0.005</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">14.5 &#x000b1; 0.051</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>P Value</bold>
</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td><td style="vertical-align: middle;text-align: center;" rowspan="1" colspan="1">&#x0003c; 0.05</td></tr></tbody></table><table-wrap-foot><fn id="fn17480"><p><sup>a</sup> Data are presented as mean &#x000b1; SD.</p></fn><fn id="fn17481"><p><sup>b</sup> T3 and T4 are measured in mg/mL</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec79159"><title>5. Discussion</title><p>Based on the results, plasma concentrations of T3 and T4 increased after 30, 360, and 720 minutes of injection. The arcuate nucleus is likely to be the primary site for neurons that sense circulating fuels and energy reserves. The paraventricular nucleus (PVN) receives input from the arcuate nucleus and harbors many of the releasing factors such as corticotropin releasing factor (CRF), thyrotropin-releasing hormone (TRH), vasopressin, and oxytocin, which control release of pituitary hormones. The ventromedial nucleus receives input from the arcuate nucleus and plays a critical role in energy balance along with the arcuate nucleus (<xref rid="A17988R25" ref-type="bibr">25</xref>). The ventral-median nucleus and PVN have descending projections to the autonomic nervous system and other pathways that control ingestive behaviors and metabolism. </p><p>Menopause indicates the end of the reproductive life span of females, which is characterized by a dramatic drop in circulating estrogens. Hormone replacement therapy has been successfully used to treat menopausal symptoms. Estrogens have shown a strong suppressive effect on rat&#x02019;s GnRH and ICV injection of E2 into the third ventricle affects pituitary and thyroid function in female rats (<xref rid="A17988R21" ref-type="bibr">21</xref>). Previous studies have demonstrated that ghrelin increases synthesis of Agouti and neuropeptide Y in arcuate nucleus (<xref rid="A17988R5" ref-type="bibr">5</xref>, <xref rid="A17988R6" ref-type="bibr">6</xref>). It is also established that Agouti and neuropeptide Y immunoreactive axon densely innervate the neurons that secret TRH in the PVN of hypothalamus. Moreover, the exogenous ICV or PVN infusion of Agouti or neuropeptide Y markedly inhibits the HPT axis activity (<xref rid="A17988R23" ref-type="bibr">23</xref>, <xref rid="A17988R26" ref-type="bibr">26</xref>). Therefore, ghrelin might have an inhibitory effect on thyroid axis activity via increasing Agouti or neuropeptide Y. Furthermore, it has been found that Agouti acts as an endogenous antagonist or inverse agonist at melanocortin receptors on TRH neurons. Some studies have shown that alpha-melanocyte-stimulating hormone (&#x003b1;-MSH) neurons of arcuate densely innervate the TRH neurons of PVN. Therefore, there is a significant increase in TSH and thyroid hormones level after ICV or paraventricular injection of &#x003b1;-MSH (<xref rid="A17988R23" ref-type="bibr">23</xref>, <xref rid="A17988R27" ref-type="bibr">27</xref>, <xref rid="A17988R28" ref-type="bibr">28</xref>). Hence, we could expect inhibitory activity of ghrelin on HPT axis, at least partially, which might be due to an increase in the Agouti level and its antagonist action on &#x003b1;-MSH receptors. It has been suggested that central ghrelin blocks GABA release from Agouti or neuropeptide Y neurons of hypothalamus. Inhibition of GABA release is involved in the activation of CRF neurons and increasing corticotropin releasing hormone (CRH) from the hypothalamus (<xref rid="A17988R25" ref-type="bibr">25</xref>). As CRH and cortisol exert an inhibitory effect on plasma T3 and T4 concentrations (<xref rid="A17988R29" ref-type="bibr">29</xref>, <xref rid="A17988R30" ref-type="bibr">30</xref>). Inhibitory effect of ghrelin on thyroid axis might be partially due to its stimulatory effect on hypothalamus-pituitary-adrenal axis. Previous studies have shown that E2 blocks the stimulatory effect of ghrelin on arcuate nucleus of the hypothalamus. There is a great bulk of published data on the value of estrogen replacement therapy in alleviating menopausal symptoms such as hot flushes and insomnia and preventing urogenital atrophy and osteoporosis (<xref rid="A17988R31" ref-type="bibr">31</xref>). During hormonal therapy, both beneficial and undesirable effects appear due to multiple target organs for estrogens (<xref rid="A17988R30" ref-type="bibr">30</xref>). Epidemiologic studies suggest that the use of estrogens might contribute to the pathogenesis of thyroid tumors (<xref rid="A17988R32" ref-type="bibr">32</xref>). In addition, thyroid diseases are more common in females (<xref rid="A17988R33" ref-type="bibr">33</xref>). Although some studies demonstrated the effects of estrogens on the development, physiology, and histology of the thyroid gland, questions about the effects of estrogen replacement therapy on the thyroid gland remained unanswered (<xref rid="A17988R34" ref-type="bibr">34</xref>). Regarding the effect of E2 on thyroid activity, numerous studies have demonstrated contradictory results such as stimulatory effect through activation of pituitary-thyroid-axis following E2 treatment. Effects of estrogens have been reported in various hypothalamic nuclei, including PVN, ventral-median, and arcuate nucleuses (<xref rid="A17988R20" ref-type="bibr">20</xref>, <xref rid="A17988R22" ref-type="bibr">22</xref>). </p><p>To investigate functional significance of E2 receptor in these brain areas, we examined neuropeptide characteristics of E2 receptor-expressing neurons in the PVN of female rats using dual label immunocytochemistry. TRH expression in PVN of cycling rats and functional differences between the PVN and the ventral-median nucleus for neurotransmitter content and/or connectivity are responsible for the different effects of E2 administration on HPT axis activity in these nuclei. Within the hypothalamus, the PVN is the most important nucleus when it comes to determine HPT axis activity (<xref rid="A17988R35" ref-type="bibr">35</xref>, <xref rid="A17988R36" ref-type="bibr">36</xref>). Nuclear E2 receptor alpha was found in a population of TRH expressing neurons in the PVN. The neurons accumulate TRH in PVN. Interaction between E2 receptor and TRH neurons increases TSH, which leads to secretion of T3 and T4 (<xref rid="A17988R37" ref-type="bibr">37</xref>). Previous studies have shown that E2 decreases the stimulatory effect of ghrelin on arcuate nucleus of hypothalamus. E2 binds to E2 receptor alpha on unidentified neurons of arcuate nucleus and reduces activity of agouti and neuropeptide Y, which is followed by reduction of food intake and effect of ghrelin on thyroid hormones (<xref rid="A17988R35" ref-type="bibr">35</xref>). </p><p>In the present study, the effect of ghrelin and E2 on thyroid axis was investigated for the first time. The results demonstrated that E2 significantly decreased the inhibitory effect of ghrelin on mean plasma T3 and T4 concentrations. </p></sec></body><back><ack><p>We would like to appreciate Mr. Ghaffari and Mrs. Fariba Mahmoudi helps from Shahid Beheshti University, Tehran, Iran.</p></ack><ref-list><title>References</title><ref id="A17988R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellokoski</surname><given-names>E</given-names></name><name><surname>Poykko</surname><given-names>SM</given-names></name><name><surname>Karjalainen</surname><given-names>AH</given-names></name><name><surname>Ukkola</surname><given-names>O</given-names></name><name><surname>Heikkinen</surname><given-names>J</given-names></name><name><surname>Kesaniemi</surname><given-names>YA</given-names></name><etal>et al.</etal></person-group><article-title>Estrogen replacement therapy increases plasma ghrelin levels.</article-title><source>J Clin Endocrinol Metab.</source><year>2005</year><volume>90</volume><issue>5</issue><fpage>2954</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-2016</pub-id><pub-id pub-id-type="pmid">15872336</pub-id></element-citation></ref><ref id="A17988R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedmer</surname><given-names>P</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>D'Alessio</surname><given-names>D</given-names></name><name><surname>Tschop</surname><given-names>MH</given-names></name></person-group><article-title>Ghrelin, obesity and diabetes.</article-title><source>Nat Clin Pract Endocrinol Metab.</source><year>2007</year><volume>3</volume><issue>10</issue><fpage>705</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/ncpendmet0625</pub-id><pub-id pub-id-type="pmid">17893689</pub-id></element-citation></ref><ref id="A17988R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>H</given-names></name><name><surname>Date</surname><given-names>Y</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach.</article-title><source>Nature.</source><year>1999</year><volume>402</volume><issue>6762</issue><fpage>656</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/45230</pub-id><pub-id pub-id-type="pmid">10604470</pub-id></element-citation></ref><ref id="A17988R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name></person-group><article-title>Ghrelin: structure and function.</article-title><source>Physiol Rev.</source><year>2005</year><volume>85</volume><issue>2</issue><fpage>495</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1152/physrev.00012.2004</pub-id><pub-id pub-id-type="pmid">15788704</pub-id></element-citation></ref><ref id="A17988R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamegai</surname><given-names>J</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name><name><surname>Sugihara</surname><given-names>H</given-names></name><name><surname>Wakabayashi</surname><given-names>I</given-names></name></person-group><article-title>Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats.</article-title><source>Diabetes.</source><year>2001</year><volume>50</volume><issue>11</issue><fpage>2438</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11679419</pub-id></element-citation></ref><ref id="A17988R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wren</surname><given-names>AM</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Abbott</surname><given-names>CR</given-names></name><name><surname>Dhillo</surname><given-names>WS</given-names></name><name><surname>Seal</surname><given-names>LJ</given-names></name><name><surname>Cohen</surname><given-names>MA</given-names></name><etal>et al.</etal></person-group><article-title>Ghrelin causes hyperphagia and obesity in rats.</article-title><source>Diabetes.</source><year>2001</year><volume>50</volume><issue>11</issue><fpage>2540</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11679432</pub-id></element-citation></ref><ref id="A17988R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Kral</surname><given-names>JG</given-names></name></person-group><article-title>Ghrelin: integrative neuroendocrine peptide in health and disease.</article-title><source>Ann Surg.</source><year>2004</year><volume>239</volume><issue>4</issue><fpage>464</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15024307</pub-id></element-citation></ref><ref id="A17988R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asakawa</surname><given-names>A</given-names></name><name><surname>Inui</surname><given-names>A</given-names></name><name><surname>Kaga</surname><given-names>T</given-names></name><name><surname>Katsuura</surname><given-names>G</given-names></name><name><surname>Fujimiya</surname><given-names>M</given-names></name><name><surname>Fujino</surname><given-names>MA</given-names></name><etal>et al.</etal></person-group><article-title>Antagonism of ghrelin receptor reduces food intake and body weight gain in mice.</article-title><source>Gut.</source><year>2003</year><volume>52</volume><issue>7</issue><fpage>947</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12801949</pub-id></element-citation></ref><ref id="A17988R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatti</surname><given-names>SF</given-names></name><name><surname>Duchateau</surname><given-names>L</given-names></name><name><surname>Van Ham</surname><given-names>LM</given-names></name><name><surname>De Vliegher</surname><given-names>SP</given-names></name><name><surname>Mol</surname><given-names>JA</given-names></name><name><surname>Rijnberk</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Effects of growth hormone secretagogues on the release of adenohypophyseal hormones in young and old healthy dogs.</article-title><source>Vet J.</source><year>2006</year><volume>172</volume><issue>3</issue><fpage>515</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2005.04.025</pub-id><pub-id pub-id-type="pmid">15951209</pub-id></element-citation></ref><ref id="A17988R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>SG</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name></person-group><article-title>[Inhibition of dopamine on WDR neurons of dorsal horn not antagonized by phentolamine and naloxone in rats].</article-title><source>Sheng Li Xue Bao.</source><year>1992</year><volume>44</volume><issue>4</issue><fpage>362</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1293749</pub-id></element-citation></ref><ref id="A17988R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Stanley</surname><given-names>SA</given-names></name><name><surname>Morgan</surname><given-names>DG</given-names></name><name><surname>Seal</surname><given-names>LJ</given-names></name><name><surname>Kong</surname><given-names>WM</given-names></name><etal>et al.</etal></person-group><article-title>The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin.</article-title><source>J Clin Invest.</source><year>2000</year><volume>105</volume><issue>7</issue><fpage>1005</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1172/JCI8857</pub-id><pub-id pub-id-type="pmid">10749579</pub-id></element-citation></ref><ref id="A17988R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wren</surname><given-names>AM</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Ward</surname><given-names>HL</given-names></name><name><surname>Murphy</surname><given-names>KG</given-names></name><name><surname>Dakin</surname><given-names>CL</given-names></name><name><surname>Taheri</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion.</article-title><source>Endocrinology.</source><year>2000</year><volume>141</volume><issue>11</issue><fpage>4325</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1210/endo.141.11.7873</pub-id><pub-id pub-id-type="pmid">11089570</pub-id></element-citation></ref><ref id="A17988R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluge</surname><given-names>M</given-names></name><name><surname>Riedl</surname><given-names>S</given-names></name><name><surname>Uhr</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yassouridis</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Ghrelin affects the hypothalamus-pituitary-thyroid axis in humans by increasing free thyroxine and decreasing TSH in plasma.</article-title><source>Eur J Endocrinol.</source><year>2010</year><volume>162</volume><issue>6</issue><fpage>1059</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1530/EJE-10-0094</pub-id><pub-id pub-id-type="pmid">20423986</pub-id></element-citation></ref><ref id="A17988R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname><given-names>K</given-names></name><name><surname>Ariyasu</surname><given-names>H</given-names></name><name><surname>Kanamoto</surname><given-names>N</given-names></name><name><surname>Iwakura</surname><given-names>H</given-names></name><name><surname>Yoshimoto</surname><given-names>A</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><etal>et al.</etal></person-group><article-title>Ghrelin strongly stimulates growth hormone release in humans.</article-title><source>J Clin Endocrinol Metab.</source><year>2000</year><volume>85</volume><issue>12</issue><fpage>4908</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1210/jcem.85.12.7167</pub-id><pub-id pub-id-type="pmid">11134161</pub-id></element-citation></ref><ref id="A17988R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sze</surname><given-names>PY</given-names></name><name><surname>Yanai</surname><given-names>J</given-names></name><name><surname>Ginsburg</surname><given-names>BE</given-names></name></person-group><article-title>Effects of early ethanol input on the activities of ethanol-metabolizing enzymes in mice.</article-title><source>Biochem Pharmacol.</source><year>1976</year><volume>25</volume><issue>2</issue><fpage>215</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1259786</pub-id></element-citation></ref><ref id="A17988R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Zakharov</surname><given-names>MN</given-names></name><name><surname>Khan</surname><given-names>SH</given-names></name><name><surname>Miki</surname><given-names>R</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Toraldo</surname><given-names>G</given-names></name><etal>et al.</etal></person-group><article-title>The dynamic structure of the estrogen receptor.</article-title><source>J Amino Acids.</source><year>2011</year><volume>2011</volume><fpage>812540</fpage><pub-id pub-id-type="doi">10.4061/2011/812540</pub-id><pub-id pub-id-type="pmid">22312471</pub-id></element-citation></ref><ref id="A17988R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>GE</given-names></name><name><surname>McArthur</surname><given-names>S</given-names></name></person-group><article-title>Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.</article-title><source>Pharmacol Rev.</source><year>2010</year><volume>62</volume><issue>2</issue><fpage>155</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1124/pr.109.002071</pub-id><pub-id pub-id-type="pmid">20392807</pub-id></element-citation></ref><ref id="A17988R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Bisschop</surname><given-names>PH</given-names></name><name><surname>Eggels</surname><given-names>L</given-names></name><name><surname>Foppen</surname><given-names>E</given-names></name><name><surname>Fliers</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>JN</given-names></name><etal>et al.</etal></person-group><article-title>Intrahypothalamic estradiol modulates hypothalamus-pituitary-adrenal-axis activity in female rats.</article-title><source>Endocrinology.</source><year>2012</year><volume>153</volume><issue>7</issue><fpage>3337</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1210/en.2011-2176</pub-id><pub-id pub-id-type="pmid">22562172</pub-id></element-citation></ref><ref id="A17988R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Dayem</surname><given-names>MM</given-names></name><name><surname>Elgendy</surname><given-names>MS</given-names></name></person-group><article-title>Effects of chronic estradiol treatment on the thyroid gland structure and function of ovariectomized rats.</article-title><source>BMC Res Notes.</source><year>2009</year><volume>2</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/1756-0500-2-173</pub-id><pub-id pub-id-type="pmid">19715616</pub-id></element-citation></ref><ref id="A17988R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisschop</surname><given-names>PH</given-names></name><name><surname>Toorians</surname><given-names>AW</given-names></name><name><surname>Endert</surname><given-names>E</given-names></name><name><surname>Wiersinga</surname><given-names>WM</given-names></name><name><surname>Gooren</surname><given-names>LJ</given-names></name><name><surname>Fliers</surname><given-names>E</given-names></name></person-group><article-title>The effects of sex-steroid administration on the pituitary-thyroid axis in transsexuals.</article-title><source>Eur J Endocrinol.</source><year>2006</year><volume>155</volume><issue>1</issue><fpage>11</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1530/eje.1.02192</pub-id><pub-id pub-id-type="pmid">16793944</pub-id></element-citation></ref><ref id="A17988R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>N</given-names></name><name><surname>Islander</surname><given-names>U</given-names></name><name><surname>Egecioglu</surname><given-names>E</given-names></name><name><surname>Lof</surname><given-names>E</given-names></name><name><surname>Swanson</surname><given-names>C</given-names></name><name><surname>Moverare-Skrtic</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>Investigation of central versus peripheral effects of estradiol in ovariectomized mice.</article-title><source>J Endocrinol.</source><year>2005</year><volume>187</volume><issue>2</issue><fpage>303</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1677/joe.1.06181</pub-id><pub-id pub-id-type="pmid">16293778</pub-id></element-citation></ref><ref id="A17988R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitcher</surname><given-names>JL</given-names></name></person-group><article-title>Presidential address 1988. The future of gastrointestinal endoscopy and the A/S/G/E: will we continue to lead or be led?</article-title><source>Gastrointest Endosc.</source><year>1988</year><volume>34</volume><issue>5</issue><fpage>377</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">3181696</pub-id></element-citation></ref><ref id="A17988R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekete</surname><given-names>C</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Mihaly</surname><given-names>E</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Rand</surname><given-names>WM</given-names></name><name><surname>Legradi</surname><given-names>G</given-names></name><etal>et al.</etal></person-group><article-title>Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis.</article-title><source>Endocrinology.</source><year>2001</year><volume>142</volume><issue>6</issue><fpage>2606</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1210/endo.142.6.8207</pub-id><pub-id pub-id-type="pmid">11356711</pub-id></element-citation></ref><ref id="A17988R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rendell-Baker</surname><given-names>L</given-names></name></person-group><article-title>A babies' light-weight suction endotracheal connector.</article-title><source>Br J Anaesth.</source><year>1956</year><volume>28</volume><issue>2</issue><fpage>87</fpage><pub-id pub-id-type="pmid">13293289</pub-id></element-citation></ref><ref id="A17988R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>YH</given-names></name><name><surname>Chua</surname><given-names>S, Jr.</given-names></name></person-group><article-title>Transcription factors in the development of medial hypothalamic structures.</article-title><source>Am J Physiol Endocrinol Metab.</source><year>2009</year><volume>297</volume><issue>3</issue><fpage>E563</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00064.2009</pub-id><pub-id pub-id-type="pmid">19383874</pub-id></element-citation></ref><ref id="A17988R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legradi</surname><given-names>G</given-names></name><name><surname>Lechan</surname><given-names>RM</given-names></name></person-group><article-title>Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus.</article-title><source>Endocrinology.</source><year>1999</year><volume>140</volume><issue>8</issue><fpage>3643</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1210/endo.140.8.6935</pub-id><pub-id pub-id-type="pmid">10433222</pub-id></element-citation></ref><ref id="A17988R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekete</surname><given-names>C</given-names></name><name><surname>Legradi</surname><given-names>G</given-names></name><name><surname>Mihaly</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>QH</given-names></name><name><surname>Tatro</surname><given-names>JB</given-names></name><name><surname>Rand</surname><given-names>WM</given-names></name><etal>et al.</etal></person-group><article-title>alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression.</article-title><source>J Neurosci.</source><year>2000</year><volume>20</volume><issue>4</issue><fpage>1550</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10662844</pub-id></element-citation></ref><ref id="A17988R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurazawa</surname><given-names>N</given-names></name><name><surname>Mano-Otagiri</surname><given-names>A</given-names></name><name><surname>Nemoto</surname><given-names>T</given-names></name><name><surname>Shibasaki</surname><given-names>T</given-names></name></person-group><article-title>Effects of intracerebroventricular ghrelin on food intake and Fos expression in the arcuate nucleus of the hypothalamus in female rats vary with estrous cycle phase.</article-title><source>Neurosci Lett.</source><year>2013</year><volume>541</volume><fpage>204</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.02.006</pub-id><pub-id pub-id-type="pmid">23435434</pub-id></element-citation></ref><ref id="A17988R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>R</given-names></name><name><surname>Picu</surname><given-names>A</given-names></name><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>Bonelli</surname><given-names>L</given-names></name><name><surname>Baldi</surname><given-names>M</given-names></name><name><surname>Berardelli</surname><given-names>R</given-names></name><etal>et al.</etal></person-group><article-title>Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.</article-title><source>Pituitary.</source><year>2004</year><volume>7</volume><issue>4</issue><fpage>243</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11102-005-1173-6</pub-id><pub-id pub-id-type="pmid">16132204</pub-id></element-citation></ref><ref id="A17988R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaszberenyi</surname><given-names>M</given-names></name><name><surname>Bujdoso</surname><given-names>E</given-names></name><name><surname>Bagosi</surname><given-names>Z</given-names></name><name><surname>Telegdy</surname><given-names>G</given-names></name></person-group><article-title>Mediation of the behavioral, endocrine and thermoregulatory actions of ghrelin.</article-title><source>Horm Behav.</source><year>2006</year><volume>50</volume><issue>2</issue><fpage>266</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.yhbeh.2006.03.010</pub-id><pub-id pub-id-type="pmid">16643913</pub-id></element-citation></ref><ref id="A17988R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>SL</given-names></name></person-group><article-title>Long-term use of hormone therapy for urogenital complaints: is there a role?</article-title><source>Med Clin North Am.</source><year>2003</year><volume>87</volume><issue>5</issue><fpage>1029</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14621329</pub-id></element-citation></ref><ref id="A17988R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ron</surname><given-names>E</given-names></name><name><surname>Kleinerman</surname><given-names>RA</given-names></name><name><surname>Boice</surname><given-names>JD, Jr.</given-names></name><name><surname>LiVolsi</surname><given-names>VA</given-names></name><name><surname>Flannery</surname><given-names>JT</given-names></name><name><surname>Fraumeni</surname><given-names>JD, Jr.</given-names></name></person-group><article-title>A population-based case-control study of thyroid cancer.</article-title><source>J Natl Cancer Inst.</source><year>1987</year><volume>79</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">3474436</pub-id></element-citation></ref><ref id="A17988R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollowell</surname><given-names>JG</given-names></name><name><surname>Staehling</surname><given-names>NW</given-names></name><name><surname>Flanders</surname><given-names>WD</given-names></name><name><surname>Hannon</surname><given-names>WH</given-names></name><name><surname>Gunter</surname><given-names>EW</given-names></name><name><surname>Spencer</surname><given-names>CA</given-names></name><etal>et al.</etal></person-group><article-title>Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).</article-title><source>J Clin Endocrinol Metab.</source><year>2002</year><volume>87</volume><issue>2</issue><fpage>489</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1210/jcem.87.2.8182</pub-id><pub-id pub-id-type="pmid">11836274</pub-id></element-citation></ref><ref id="A17988R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banu</surname><given-names>SK</given-names></name><name><surname>Arosh</surname><given-names>JA</given-names></name><name><surname>Govindarajulu</surname><given-names>P</given-names></name><name><surname>Aruldhas</surname><given-names>MM</given-names></name></person-group><article-title>Testosterone and estradiol differentially regulate thyroid growth in Wistar rats from immature to adult age.</article-title><source>Endocr Res.</source><year>2001</year><volume>27</volume><issue>4</issue><fpage>447</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">11794468</pub-id></element-citation></ref><ref id="A17988R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>KA</given-names></name><name><surname>Martin</surname><given-names>NM</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Hypothalamic regulation of food intake and clinical therapeutic applications.</article-title><source>Arq Bras Endocrinol Metabol.</source><year>2009</year><volume>53</volume><issue>2</issue><fpage>120</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19466203</pub-id></element-citation></ref><ref id="A17988R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ing</surname><given-names>NH</given-names></name><name><surname>Tornesi</surname><given-names>MB</given-names></name></person-group><article-title>Estradiol up-regulates estrogen receptor and progesterone receptor gene expression in specific ovine uterine cells.</article-title><source>Biol Reprod.</source><year>1997</year><volume>56</volume><issue>5</issue><fpage>1205</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9160720</pub-id></element-citation></ref><ref id="A17988R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uribe</surname><given-names>RM</given-names></name><name><surname>Zacarias</surname><given-names>M</given-names></name><name><surname>Corkidi</surname><given-names>G</given-names></name><name><surname>Cisneros</surname><given-names>M</given-names></name><name><surname>Charli</surname><given-names>JL</given-names></name><name><surname>Joseph-Bravo</surname><given-names>P</given-names></name></person-group><article-title>17beta-Oestradiol indirectly inhibits thyrotrophin-releasing hormone expression in the hypothalamic paraventricular nucleus of female rats and blunts thyroid axis response to cold exposure.</article-title><source>J Neuroendocrinol.</source><year>2009</year><volume>21</volume><issue>5</issue><fpage>439</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2826.2009.01861.x</pub-id><pub-id pub-id-type="pmid">19302192</pub-id></element-citation></ref></ref-list></back></article>